Combination of low-dose cisplatin and gemcitabine for treatment of elderly patients with advanced non-small-cell lung cancer

被引:51
作者
Feliu, J
Martín, G
Madroñal, C
Rodríguez-Jaráiz, A
Castro, J
Rodríguez, A
Checa, T
Bolaño, M
Casado, E
González-Barón, M
机构
[1] Hosp La Paz, Med Oncol Serv, Madrid 28046, Spain
[2] Hosp Clin Salamanca, Med Oncol Serv, Salamanca, Spain
[3] Hosp Clin Corrochan, Med Oncol Serv, Barcelona, Spain
[4] Hosp San Pedro de Alcantara, Med Oncol Serv, Caceres, Spain
关键词
non-small-cell lung cancer; elderly; gemcitabine; cisplatin; chemotherapy;
D O I
10.1007/s00280-003-0638-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To evaluate the feasibility, toxicity and efficacy of the combination of low-dose cisplatin (CDDP) and gemcitabine (GEM) in elderly patients with advanced non-small-cell lung cancer (NSCLC). Patients and methods: This phase II trial included 46 patients aged 70 years or older with previously untreated advanced NSCLC. All patients were evaluable for response and toxicity. Treatment consisted of CDDP 50 mg/m(2) on day 1 plus GEM 1000 mg/m(2) on days 1 and 8. The regimen was repeated every 21 days. Patients received a minimum of three courses unless progressive disease was detected. Results: A total of 190 GEMCDDP courses were administered (median 4.1 courses per patient). The chemotherapy regimen was well tolerated. No patients developed grade 4 toxicity. Grade 3 toxicities were as follows: neutropenia in six patients (13%), and anemia, thrombopenia and nausea/vomiting in one (2%) each. Two patients (4%) had mild nephrotoxicity. Of the 46 patients, 16 had a partial response (35%, 95% confidence interval, CI, 28-52%), 17 (37%) remained stable and 13 (28%) had disease progression. Eastern Cooperative Oncology Group performance status improved in 17 patients (37%), whereas 25 (54%, 95% CI 44-74%) showed a clinical benefit. Median time to progression was 20 weeks. Overall median survival was 44 weeks, with a I-year actuarial survival rate of 35%. Conclusions: The combination of low-dose CDDP and GEM for elderly patients with advanced NSCLC is an effective and well-tolerated chemotherapeutic approach.
引用
收藏
页码:247 / 252
页数:6
相关论文
共 50 条
[31]   A three-drug regimen (gemcitabine, ifosfamide and cisplatin) for advanced non-small-cell lung cancer [J].
Tognoni, A ;
Pensa, F ;
Vaira, F ;
Vigani, A ;
Bancalari, L ;
Fiasella, L ;
Maggiani, R ;
Canessa, P ;
Pronzato, P .
JOURNAL OF CHEMOTHERAPY, 2001, 13 (02) :202-205
[32]   Sunitinib in combination with gemcitabine plus cisplatin for advanced non-small cell lung cancer: A phase I dose-escalation study [J].
Reck, Martin ;
Frickhofen, Norbert ;
Cedres, Susana ;
Gatzemeier, Ulrich ;
Heigener, David ;
Fuhr, Heinz-Georg ;
Thall, Aron ;
Lanzalone, Silvana ;
Stephenson, Patricia ;
Ruiz-Garcia, Ana ;
Chao, Richard ;
Felip, Enriqueta .
LUNG CANCER, 2010, 70 (02) :180-187
[33]   Sorafenib in combination with erlotinib or with gemcitabine in elderly patients with advanced non-small-cell lung cancer: a randomized phase II study [J].
Gridelli, C. ;
Morgillo, F. ;
Favaretto, A. ;
de Marinis, F. ;
Chella, A. ;
Cerea, G. ;
Mattioli, R. ;
Tortora, G. ;
Rossi, A. ;
Fasano, M. ;
Pasello, G. ;
Ricciardi, S. ;
Maione, P. ;
Di Maio, M. ;
Ciardiello, F. .
ANNALS OF ONCOLOGY, 2011, 22 (07) :1528-1534
[34]   First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial [J].
Wachters, FM ;
van Putten, JWG ;
Kramer, H ;
Erjavec, Z ;
Eppinga, P ;
Strijbos, JH ;
de Leede, GPJ ;
Boezen, HM ;
de Vries, EGE ;
Groen, HJM .
BRITISH JOURNAL OF CANCER, 2003, 89 (07) :1192-1199
[35]   First-line gemcitabine with cisplatin or epirubicin in advanced non-small-cell lung cancer: a phase III trial [J].
F M Wachters ;
J W G van Putten ;
H Kramer ;
Z Erjavec ;
P Eppinga ;
J H Strijbos ;
G P J de Leede ;
H M Boezen ;
E G E de Vries ;
H J M Groen .
British Journal of Cancer, 2003, 89 :1192-1199
[36]   Trends in chemotherapy for elderly patients with advanced non-small-cell lung cancer [J].
Kim, Young Hak ;
Yoh, Kiyotaka ;
Niho, Seiji ;
Goto, Koichi ;
Ohmatsu, Hironobu ;
Kubota, Kaoru ;
Nishiwaki, Yutaka .
RESPIRATORY MEDICINE, 2010, 104 (03) :434-439
[37]   Erlotinib and Gefitinib for Elderly Patients with Advanced Non-small-cell Lung Cancer [J].
Passaro, Antonio ;
Alesini, Daniele ;
Pochesci, Alessia ;
Cortesi, Enrico .
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (05) :646-650
[38]   Phase II Randomized Study of Vandetanib Plus Gemcitabine or Gemcitabine Plus Placebo as First-Line Treatment of Advanced Non-Small-Cell Lung Cancer in Elderly Patients [J].
Gridelli, Cesare ;
Novello, Silvia ;
Zilembo, Nicoletta ;
Luciani, Andrea ;
Favaretto, Adolfo Gino ;
De Marinis, Filippo ;
Genestreti, Giovenzio ;
Crino, Lucio ;
Grossi, Francesco ;
Caffo, Orazio ;
Ferrau, Francesco ;
Cruciani, Giorgio ;
Brandes, Alba Ariela ;
Galetta, Domenico ;
Barni, Sandro ;
Fasola, Gianpiero ;
Cerea, Giulio ;
Ferrari, Silvia ;
Iannacone, Claudio ;
Ciardiello, Fortunato .
JOURNAL OF THORACIC ONCOLOGY, 2014, 9 (05) :733-737
[39]   Gemcitabine, vinorelbine and cisplatin combination chemotherapy in advanced non-small cell lung cancer:: a phase II trial [J].
Laack, E ;
Mende, T ;
Dürk, H ;
Kneba, M ;
Dickgreber, N ;
Welte, T ;
Müller, T ;
Scholtze, J ;
Graeven, U ;
Jasiewicz, Y ;
Edler, L ;
Hossfeld, DK .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (05) :654-660
[40]   Combination of gemcitabine and cisplatin for advanced non-small cell lung cancer: a phase II study with emphasis on scheduling [J].
Huisman, C ;
Giaccone, G ;
van Groeningen, CJ ;
Sutedja, G ;
Postmus, PE ;
Smit, EF .
LUNG CANCER, 2001, 33 (2-3) :267-275